Profile data is unavailable for this security.
About the company
GSK plc is a global biopharma company. The Company makes vaccines and specialty medicines to prevent and treat disease. Its segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed a new monoclonal antibody treatment for COVID-19. Its product areas include vaccines, specialty medicines, and general medicines. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions, including the chronic autoimmune condition lupus, respiratory disease, and human immunodeficiency virus (HIV). Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics and medicines for skin diseases. It has a global network of about 12 vaccines manufacturing sites.
- Revenue in USD (TTM)37.64bn
- Net income in USD4.19bn
- Incorporated1999
- Employees90.10k
- LocationGSK plc980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
- Phone+44 208 047 5000
- Fax+44 208 047 7807
- Websitehttps://www.gsk.com/
Mergers & acquisitions
| Acquired company | GSK:LSE since announced | Transaction value |
|---|---|---|
| Affinivax Inc | -33.95% | 3.30bn |
| Sierra Oncology Inc | -36.02% | 2.08bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DuPont de Nemours Inc | 14.18bn | 1.16bn | 34.45bn | 28.00k | 30.30 | 1.38 | 13.83 | 2.43 | 2.29 | 3.63 | 27.84 | 50.15 | 0.3148 | 3.54 | 5.49 | 506,571.40 | 2.71 | -0.2227 | 3.11 | -0.2892 | 35.05 | 31.60 | 8.62 | -1.61 | 1.99 | 5.11 | 0.3173 | -- | 16.15 | -19.13 | 172.14 | -15.09 | -25.20 | -26.30 |
| Iqvia Holdings Inc | 14.31bn | 1.18bn | 39.83bn | 83.00k | 34.90 | 7.45 | 17.88 | 2.78 | 6.15 | 6.15 | 74.43 | 28.78 | 0.593 | -- | 5.76 | 181,101.30 | 4.94 | 1.77 | 6.25 | 2.14 | 34.72 | 34.30 | 8.34 | 3.64 | -- | 5.19 | 0.6986 | 0.00 | 22.14 | 15.28 | 246.24 | 68.08 | 31.30 | -- |
| Moderna Inc | 21.39bn | 11.77bn | 67.38bn | 2.70k | 6.34 | 3.77 | 5.56 | 3.15 | 27.65 | 27.65 | 50.69 | 46.49 | 0.9106 | 2.93 | 7.33 | 7,922,222.00 | 50.09 | 41.17 | 77.88 | 66.78 | 79.20 | -- | 55.00 | 52.35 | 1.80 | -- | 0.0599 | 0.00 | 2,199.12 | 179.44 | 1,733.33 | -- | 53.67 | -- |
| GSK plc (ADR) | 37.64bn | 4.19bn | 68.61bn | 90.10k | 14.23 | -- | 8.34 | 1.82 | 2.37 | 8.44 | 20.64 | -- | 0.4529 | 2.00 | 4.14 | 417,752.30 | 6.08 | 6.96 | 9.42 | 11.61 | 65.41 | 68.48 | 13.43 | 14.68 | 0.744 | 10.20 | 0.7173 | 94.85 | 0.044 | 4.11 | -23.73 | 36.90 | 4.50 | -- |
| Zoetis Inc | 8.01bn | 2.07bn | 69.04bn | 12.10k | 33.86 | 14.82 | 27.32 | 8.62 | 4.38 | 4.38 | 16.94 | 10.00 | 0.5849 | 1.14 | 6.84 | 661,735.60 | 15.08 | 13.79 | 17.93 | 16.04 | 70.19 | 68.75 | 25.78 | 23.94 | 1.48 | 12.19 | 0.5847 | 22.53 | 16.49 | 9.73 | 24.36 | 19.93 | 17.17 | 20.72 |
| Regeneron Pharmaceuticals Inc | 13.71bn | 5.37bn | 80.75bn | 10.37k | 15.64 | 3.76 | 14.16 | 5.89 | 47.40 | 47.40 | 120.98 | 197.05 | 0.534 | 0.8967 | 2.49 | 1,322,357.00 | 20.92 | 25.64 | 24.00 | 29.99 | 85.39 | 88.51 | 39.17 | 39.11 | 4.52 | 20.54 | 0.1119 | -- | 89.14 | 27.02 | 129.86 | 55.24 | 1.52 | -- |
| Vertex Pharmaceuticals Incorporated | 8.70bn | 3.27bn | 80.93bn | 3.90k | 24.88 | 6.21 | 23.69 | 9.30 | 12.67 | 12.67 | 33.69 | 50.77 | 0.5934 | 2.89 | 7.00 | 2,230,913.00 | 22.32 | 18.01 | 26.40 | 21.87 | 88.00 | 87.77 | 37.62 | 29.17 | 4.55 | 32.16 | 0.0328 | 0.00 | 22.06 | 34.79 | -13.63 | -- | 32.96 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Dodge & Coxas of 30 Sep 2022 | 58.58m | 2.88% |
| Fisher Asset Management LLCas of 30 Sep 2022 | 12.17m | 0.60% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 2022 | 11.18m | 0.55% |
| Capital Research & Management Co. (International Investors)as of 30 Sep 2022 | 11.07m | 0.54% |
| Renaissance Technologies LLCas of 30 Sep 2022 | 9.35m | 0.46% |
| Arrowstreet Capital LPas of 30 Sep 2022 | 8.05m | 0.40% |
| Goldman Sachs Asset Management LPas of 30 Sep 2022 | 7.63m | 0.38% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2022 | 7.58m | 0.37% |
| SSgA Funds Management, Inc.as of 30 Sep 2022 | 7.57m | 0.37% |
| Two Sigma Investments LPas of 30 Sep 2022 | 7.14m | 0.35% |
